Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-07-01
2000-07-25
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514415, 514423, 514460, 514547, 514601, 514602, 514603, 514604, 514625, A61K 3118, A61K 3116, A61K 31435, A61K 31405, A61K 3140, A61K 3135, A61K 31225
Patent
active
06093719&
ABSTRACT:
The present invention is a combination of an ACAT inhibitor, for example, sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl) phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoportein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
REFERENCES:
Sliskovic and Trivedi, "ACAT Inhibitors: Potential Anti-atherosclerotic Agents", Current Medicinal Chemistry, vol. 1, 1994, 204-225.
LaRosa et al., "The Cholesterol Facts, A Summary of the Evidence Relating Dietary Fats, Serum Cholesterol, and Coronary Heart Disease", Circulation, vol. 81, No. 5, 1990, 1721-1733.
Gordon et al., "High Density Lipoprotein As a Protective Factor Against Coronary Heart Disease", The American Journal of Medicine, vol. 62, 1977, 707-714.
Frick et al., "Helsinki Heart Study: Primary-Prevention Trial With Gemfibrozil in Middle-Aged Men with Dyslipidemia", The New England Journal of Medicine, vol. 317, No. 20, 1987, 1237-1245.
PCT International Search Report, PCT/US96/15854.
Heinonen et al., "Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined with Colestipol", J. Cardiovasc. Pharmacol. Therapeut., vol. 1, No. 2, 1996, 117-122.
Kusunoki et al., "Studies on Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitory Effects and Enzyme Selectivity of F-1394, a Pantotheic Acid Derivative", Jpn. J. Pharmacol., vol. 67, 1995, 195-203.
Davignon, "Prospects for Drug Therapy for Hyperlipoproteinaemia" Diabete & Metabolisme, vol. 21, No. 2, 1995, 139-146.
Ed. J.E.F. Reynolds, "Martindale, the extra pharmacopoeia", The Pharmaceutical Press, London, 987-989 (1993).
CA 110:128422, Osborne et al, 1989.
Anderson Elizabeth M.
Jordan Kimberly
Warner-Lambert & Company
LandOfFree
Method and pharmaceutical composition for regulating lipid conce does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and pharmaceutical composition for regulating lipid conce, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and pharmaceutical composition for regulating lipid conce will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1336826